MedTrace Logo

Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis

NCT04867369 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2024-12-13

Study results available
· View outcomes & findings →

Summary

A phase IV, randomized, single-blind, single-center study measuring the effects of Pecs II block with 0.25% bupivacaine versus surgeon infiltration with 0.25% bupivacaine on postoperative pain control and opioid utilization in participants who undergo open subpectoral tenodesis.

Conditions

  • Tendonitis

Interventions

DRUG

Bupivacaine 20mL 0.5%

Interscalene nerve block with 20 mL 0.5% bupivacaine.

DRUG

Bupivacaine 20mL 0.25%

Pecs II fascial plane block with 20 mL 0.25% bupivacaine.

DRUG

Bupivacaine up to 15mL 0.25%

Local infiltration of 0.25% bupivacaine by the surgeon, up to 15 mL.

Sponsors & Collaborators

Principal Investigators

  • Arthur Hertling, MD · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-14
Primary Completion
2023-11-08
Completion
2023-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04867369 on ClinicalTrials.gov